Analysts at Morgan Stanley think investors won't have the stomach for certain shares if Ozempic and others like it continue to rise in popularity. The use of weight-loss drugs is showing no signs of ...
Source LinkAnalysts at Morgan Stanley think investors won't have the stomach for certain shares if Ozempic and others like it continue to rise in popularity. The use of weight-loss drugs is showing no signs of ...
Source Link
Comments